Safinamide

• Background:

  A selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A.1 Displays anticonvulsant activity2 and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models3. Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade.4 A novel therapeutic for Parkinson’s disease with multiple modes of action.5 Effective as an add-on to dopamine agonist therapy in early Parkinson’s.6

• Conjugation:

  Unconjugated

• Buffer:

  White solid

• Storage Conditions:

  -20°C